The biofoundry-as-a-service market size has grown exponentially in recent years. It will grow from $1.65 billion in 2025 to $2.01 billion in 2026 at a compound annual growth rate (CAGR) of 21.3%. The growth in the historic period can be attributed to increasing investment in synthetic biology, adoption of automated laboratory equipment, rising demand for genetic engineering services, growth of academic and research institutes, expansion of biotechnology companies.
The biofoundry-as-a-service market size is expected to see exponential growth in the next few years. It will grow to $4.38 billion in 2030 at a compound annual growth rate (CAGR) of 21.6%. The growth in the forecast period can be attributed to growing deployment of AI-driven biofoundry platforms, increasing adoption of cloud-based design-build-test-learn services, rising demand for integrated bioengineering solutions, expansion of pharmaceutical and industrial biotechnology applications, increasing focus on scalable and high-throughput biofoundry operations. Major trends in the forecast period include increasing adoption of end-to-end dbtl cycle services, rising demand for automated dna assembly services, growing integration of machine learning modeling in biofoundries, expansion of platform-as-a-service bioengineering solutions, rising focus on high-throughput phenotypic and genotypic testing.
The increasing investments in life sciences are anticipated to drive the growth of the biofoundry-as-a-service market in the future. Investments in life sciences refer to funding or allocating capital to companies, research, and technologies focused on healthcare, biotechnology, pharmaceuticals, medical devices, and related biological innovations. Such investments are growing due to rising demand for advanced healthcare solutions, as more individuals require innovative treatments, personalized medicine, and cutting-edge technologies to tackle complex diseases and improve overall health outcomes. Investments in life sciences stimulate the growth of biofoundry-as-a-service by providing the capital needed to develop advanced automated platforms, accelerate high-throughput biological research, and deliver scalable, customizable solutions for biotechnology companies and academic institutions. For instance, in September 2025, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based non-profit organization, the UK government pledged up to $707 million (£520 million) in capital grants to support inward investment in innovative life sciences manufacturing, reinforcing the country’s position as a leading hub for life sciences innovation. Therefore, the increasing investments in life sciences are driving the growth of the biofoundry-as-a-service market.
Leading companies operating in the biofoundry-as-a-service market are focusing on deploying modular, automated biofoundry platforms to accelerate biologics development, streamline process optimization, and enhance scalable manufacturing capabilities. Modular, automated biofoundry platforms are advanced laboratory systems that integrate robotics, artificial intelligence-enabled software, and standardized biological processes to streamline the design, construction, testing, and optimization of biological systems with minimal manual input. For example, in November 2024, Quotient Sciences, a UK-based drug development and manufacturing accelerator, installed Centillion’s GMP Biofoundry-in-a-Box platform to expand its integrated drug development and manufacturing services. The installation enhances the company’s ability to provide automated, high-throughput biologics development and GMP-compliant production, supporting clients with accelerated timelines, improved reproducibility, and scalable therapeutic manufacturing solutions.
In December 2023, Synplogen Inc., a gene therapy solutions company based in Japan, partnered with Ginkgo Bioworks Inc. to accelerate DNA manufacturing and gene therapy platform services in Japan. This partnership aims to increase access to high-quality DNA materials, streamline gene therapy development, and support innovative therapeutic programs for rare and complex diseases. Ginkgo Bioworks Inc., based in the US, is a biotechnology company that specializes in offering biofoundry-as-a-service (BFaaS).
Major companies operating in the biofoundry-as-a-service market are GenScript Biotech Corporation, Ginkgo Bioworks Holdings Inc., Twist Bioscience Corporation, Codexis Inc., Emerald Cloud Lab Inc., Synbio Technologies LLC, Automata Technologies Limited, Telesis Bio Inc., Culture Biosciences Inc., Bioneer Corporation, Earlham Biofoundry Ltd., Arzeda Corporation, LabGenius Limited, Conagen Inc., Bota Biosciences Inc., Arctoris Ltd., Evonetix Ltd., Absci Corporation, TeselaGen Biotechnology Inc., SynbiCITE Innovation Hub.
North America was the largest region in the biofoundry-as-a-service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biofoundry-as-a-service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biofoundry-as-a-service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The biofoundry-as-a-service market consists of revenues earned by entities by providing services such as protein expression and analysis, automated cell culture, metabolic pathway optimization, genome editing, enzyme engineering, pathway prototyping, and bioinformatics support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Biofoundry-as-a-service is a model that provides access to automated, high-throughput biological engineering facilities through remote or digital interfaces. It allows the design, construction, and testing of genetic constructs and organisms without extensive in-house infrastructure. This service accelerates synthetic biology workflows by integrating robotics, software, and data analytics into a unified platform.
The essential service types of biofoundry-as-a-service include design, build, test, learn, and integrated services. Design involves planning and engineering biological systems using automated workflows and computational tools. Applications include pharmaceuticals, agriculture, industrial biotechnology, environmental sectors, and others, serving academic and research institutes, biotechnology companies, pharmaceutical firms, and other end-users.
Tariffs on imported laboratory automation equipment, robotic systems, and analytical instruments are impacting the biofoundry-as-a-service market by increasing setup and operational costs, particularly affecting design, build, and test service segments. Regions such as North America, Europe, and Asia-Pacific, which rely on imported high-precision instruments and robotics, are most affected. While tariffs increase costs, they also incentivize local manufacturing, promote domestic service capabilities, and encourage innovation in cost-efficient, automated bioengineering platforms, creating growth opportunities for regional providers.
The biofoundry-as-a-service market research report is one of a series of new reports that provides biofoundry-as-a-service market statistics, including biofoundry-as-a-service industry global market size, regional shares, competitors with a biofoundry-as-a-service market share, detailed biofoundry-as-a-service market segments, market trends and opportunities, and any further data you may need to thrive in the biofoundry-as-a-service industry. This biofoundry-as-a-service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
The biofoundry-as-a-service market size is expected to see exponential growth in the next few years. It will grow to $4.38 billion in 2030 at a compound annual growth rate (CAGR) of 21.6%. The growth in the forecast period can be attributed to growing deployment of AI-driven biofoundry platforms, increasing adoption of cloud-based design-build-test-learn services, rising demand for integrated bioengineering solutions, expansion of pharmaceutical and industrial biotechnology applications, increasing focus on scalable and high-throughput biofoundry operations. Major trends in the forecast period include increasing adoption of end-to-end dbtl cycle services, rising demand for automated dna assembly services, growing integration of machine learning modeling in biofoundries, expansion of platform-as-a-service bioengineering solutions, rising focus on high-throughput phenotypic and genotypic testing.
The increasing investments in life sciences are anticipated to drive the growth of the biofoundry-as-a-service market in the future. Investments in life sciences refer to funding or allocating capital to companies, research, and technologies focused on healthcare, biotechnology, pharmaceuticals, medical devices, and related biological innovations. Such investments are growing due to rising demand for advanced healthcare solutions, as more individuals require innovative treatments, personalized medicine, and cutting-edge technologies to tackle complex diseases and improve overall health outcomes. Investments in life sciences stimulate the growth of biofoundry-as-a-service by providing the capital needed to develop advanced automated platforms, accelerate high-throughput biological research, and deliver scalable, customizable solutions for biotechnology companies and academic institutions. For instance, in September 2025, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based non-profit organization, the UK government pledged up to $707 million (£520 million) in capital grants to support inward investment in innovative life sciences manufacturing, reinforcing the country’s position as a leading hub for life sciences innovation. Therefore, the increasing investments in life sciences are driving the growth of the biofoundry-as-a-service market.
Leading companies operating in the biofoundry-as-a-service market are focusing on deploying modular, automated biofoundry platforms to accelerate biologics development, streamline process optimization, and enhance scalable manufacturing capabilities. Modular, automated biofoundry platforms are advanced laboratory systems that integrate robotics, artificial intelligence-enabled software, and standardized biological processes to streamline the design, construction, testing, and optimization of biological systems with minimal manual input. For example, in November 2024, Quotient Sciences, a UK-based drug development and manufacturing accelerator, installed Centillion’s GMP Biofoundry-in-a-Box platform to expand its integrated drug development and manufacturing services. The installation enhances the company’s ability to provide automated, high-throughput biologics development and GMP-compliant production, supporting clients with accelerated timelines, improved reproducibility, and scalable therapeutic manufacturing solutions.
In December 2023, Synplogen Inc., a gene therapy solutions company based in Japan, partnered with Ginkgo Bioworks Inc. to accelerate DNA manufacturing and gene therapy platform services in Japan. This partnership aims to increase access to high-quality DNA materials, streamline gene therapy development, and support innovative therapeutic programs for rare and complex diseases. Ginkgo Bioworks Inc., based in the US, is a biotechnology company that specializes in offering biofoundry-as-a-service (BFaaS).
Major companies operating in the biofoundry-as-a-service market are GenScript Biotech Corporation, Ginkgo Bioworks Holdings Inc., Twist Bioscience Corporation, Codexis Inc., Emerald Cloud Lab Inc., Synbio Technologies LLC, Automata Technologies Limited, Telesis Bio Inc., Culture Biosciences Inc., Bioneer Corporation, Earlham Biofoundry Ltd., Arzeda Corporation, LabGenius Limited, Conagen Inc., Bota Biosciences Inc., Arctoris Ltd., Evonetix Ltd., Absci Corporation, TeselaGen Biotechnology Inc., SynbiCITE Innovation Hub.
North America was the largest region in the biofoundry-as-a-service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biofoundry-as-a-service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biofoundry-as-a-service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The biofoundry-as-a-service market consists of revenues earned by entities by providing services such as protein expression and analysis, automated cell culture, metabolic pathway optimization, genome editing, enzyme engineering, pathway prototyping, and bioinformatics support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Biofoundry-as-a-service is a model that provides access to automated, high-throughput biological engineering facilities through remote or digital interfaces. It allows the design, construction, and testing of genetic constructs and organisms without extensive in-house infrastructure. This service accelerates synthetic biology workflows by integrating robotics, software, and data analytics into a unified platform.
The essential service types of biofoundry-as-a-service include design, build, test, learn, and integrated services. Design involves planning and engineering biological systems using automated workflows and computational tools. Applications include pharmaceuticals, agriculture, industrial biotechnology, environmental sectors, and others, serving academic and research institutes, biotechnology companies, pharmaceutical firms, and other end-users.
Tariffs on imported laboratory automation equipment, robotic systems, and analytical instruments are impacting the biofoundry-as-a-service market by increasing setup and operational costs, particularly affecting design, build, and test service segments. Regions such as North America, Europe, and Asia-Pacific, which rely on imported high-precision instruments and robotics, are most affected. While tariffs increase costs, they also incentivize local manufacturing, promote domestic service capabilities, and encourage innovation in cost-efficient, automated bioengineering platforms, creating growth opportunities for regional providers.
The biofoundry-as-a-service market research report is one of a series of new reports that provides biofoundry-as-a-service market statistics, including biofoundry-as-a-service industry global market size, regional shares, competitors with a biofoundry-as-a-service market share, detailed biofoundry-as-a-service market segments, market trends and opportunities, and any further data you may need to thrive in the biofoundry-as-a-service industry. This biofoundry-as-a-service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Biofoundry-as-A-Service Market Characteristics
3. Biofoundry-as-A-Service Market Supply Chain Analysis
4. Global Biofoundry-as-A-Service Market Trends and Strategies
5. Biofoundry-as-A-Service Market Analysis of End Use Industries
7. Global Biofoundry-as-A-Service Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Biofoundry-as-A-Service Total Addressable Market (TAM) Analysis for the Market
9. Biofoundry-as-A-Service Market Segmentation
10. Biofoundry-as-A-Service Market Regional and Country Analysis
11. Asia-Pacific Biofoundry-as-A-Service Market
12. China Biofoundry-as-A-Service Market
13. India Biofoundry-as-A-Service Market
14. Japan Biofoundry-as-A-Service Market
15. Australia Biofoundry-as-A-Service Market
16. Indonesia Biofoundry-as-A-Service Market
17. South Korea Biofoundry-as-A-Service Market
18. Taiwan Biofoundry-as-A-Service Market
19. South East Asia Biofoundry-as-A-Service Market
20. Western Europe Biofoundry-as-A-Service Market
21. UK Biofoundry-as-A-Service Market
22. Germany Biofoundry-as-A-Service Market
23. France Biofoundry-as-A-Service Market
24. Italy Biofoundry-as-A-Service Market
25. Spain Biofoundry-as-A-Service Market
26. Eastern Europe Biofoundry-as-A-Service Market
27. Russia Biofoundry-as-A-Service Market
28. North America Biofoundry-as-A-Service Market
29. USA Biofoundry-as-A-Service Market
30. Canada Biofoundry-as-A-Service Market
31. South America Biofoundry-as-A-Service Market
32. Brazil Biofoundry-as-A-Service Market
33. Middle East Biofoundry-as-A-Service Market
34. Africa Biofoundry-as-A-Service Market
36. Biofoundry-as-A-Service Market Competitive Landscape and Company Profiles
37. Biofoundry-as-A-Service Market Other Major and Innovative Companies
41. Biofoundry-as-A-Service Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Biofoundry-As-A-Service Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses biofoundry-as-a-service market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for biofoundry-as-a-service? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biofoundry-as-a-service market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Service Type: Design; Build; Test; Learn; Integrated Services2) By Application: Pharmaceuticals; Agriculture; Industrial Biotechnology; Environmental; Other Applications
3) By End-User: Academic and Research Institutes; Biotechnology Companies; Pharmaceutical Companies; Other End Users
Subsegments:
1) By Design: Pathway Design Services; Genetic Circuit Design Services; Strain Design and Optimization Services; Metabolic Engineering Design Services2) By Build: Automated DNA Assembly Services; Strain Construction Services; Plasmid and Vector Construction Services; Synthetic Gene Synthesis Services
3) By Test: High-Throughput Screening Services; Phenotypic Characterization Services; Genotypic Validation Services; Assay Development and Testing Services
4) By Learn: Data Analysis and Interpretation Services; Machine Learning Modeling Services; Optimization and Feedback Services; Experimental Data Integration Services
5) By Integrated Services: End-to-End Biofoundry Services; Design-Build-Test-Learn (DBTL) Cycle Services; Custom Bioengineering Project Services; Platform-As-A-Service Integrated Solutions
Companies Mentioned: GenScript Biotech Corporation; Ginkgo Bioworks Holdings Inc.; Twist Bioscience Corporation; Codexis Inc.; Emerald Cloud Lab Inc.; Synbio Technologies LLC; Automata Technologies Limited; Telesis Bio Inc.; Culture Biosciences Inc.; Bioneer Corporation; Earlham Biofoundry Ltd.; Arzeda Corporation; LabGenius Limited; Conagen Inc.; Bota Biosciences Inc.; Arctoris Ltd.; Evonetix Ltd.; Absci Corporation; TeselaGen Biotechnology Inc.; SynbiCITE Innovation Hub.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Biofoundry-as-a-Service market report include:- GenScript Biotech Corporation
- Ginkgo Bioworks Holdings Inc.
- Twist Bioscience Corporation
- Codexis Inc.
- Emerald Cloud Lab Inc.
- Synbio Technologies LLC
- Automata Technologies Limited
- Telesis Bio Inc.
- Culture Biosciences Inc.
- Bioneer Corporation
- Earlham Biofoundry Ltd.
- Arzeda Corporation
- LabGenius Limited
- Conagen Inc.
- Bota Biosciences Inc.
- Arctoris Ltd.
- Evonetix Ltd.
- Absci Corporation
- TeselaGen Biotechnology Inc.
- SynbiCITE Innovation Hub.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | May 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.01 Billion |
| Forecasted Market Value ( USD | $ 4.38 Billion |
| Compound Annual Growth Rate | 21.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
